Key facts
- Stramsen Biotech’s last known valuation is $807.0M (Oct 2023).
- It has raised $35.0M; the latest was Later Stage VC ($25.0M) in Apr 2025.
- Notable investors include Global Emerging Markets.
- Stramsen Biotech has filed 1 Form D with the SEC, most recently May 2024 ( sold).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Stramsen Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Stramsen Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stramsen Biotech
Developer of plant-based medicines intended to treat a wide range of infectious and noninfectious diseases. The company's platform leverages an extensive medicinal plant database to develop innovative treatments with improved safety profiles and reduced side effects, enabling the global healthcare market to access more effective, natural, and sustainable drugs for conditions such as cancer, cardiovascular diseases, diabetes, HIV, and more.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2020
- Website
- stramsenbiotech.com/
- Ownership
- Privately Held (backing)
Stramsen Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stramsen Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stramsen Biotech in its N-PORT filings yet. We sweep new filings monthly.